{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:18Z","timestamp":1787260998525,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctro.2026.101229","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:48:25Z","timestamp":1784098105000},"page":"101229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG)"],"prefix":"10.1016","volume":"60","author":[{"given":"Finbar","family":"Slevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Warkentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise J.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna H.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Loon","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101229_bb0005","unstructured":"European Association of Urology. Prostate cancer. 2024. Available from https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"issue":"4","key":"10.1016\/j.ctro.2026.101229_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur. Urol."},{"issue":"15","key":"10.1016\/j.ctro.2026.101229_bb0015","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate-and high-risk localized prostate cancer: results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctro.2026.101229_bb0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate Cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the Meta-analysis of randomized trials in Cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.ctro.2026.101229_bb0025","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and Meta-analysis of local salvage therapies after radiotherapy for prostate Cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101229_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate Cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"issue":"6","key":"10.1016\/j.ctro.2026.101229_bb0035","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.juro.2015.06.100","article-title":"Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate Cancer","volume":"194","author":"Zumsteg","year":"2015","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.ctro.2026.101229_bb0040","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate Cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and Oligometastasis, and future directions","volume":"211","author":"Morgan","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.ctro.2026.101229_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109672","article-title":"Salvage prostate brachytherapy in radiorecurrent prostate cancer: an international Delphi consensus study","volume":"184","author":"Corkum","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ctro.2026.101229_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: an ESTRO ACROP Delphi consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.ctro.2026.101229_bb0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijrobp.2025.01.038","article-title":"Joining forces to advance reirradiation: establishing the reirradiation COllaborative group (ReCOG)","volume":"122","author":"Mayo","year":"2025","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"issue":"1","key":"10.1016\/j.ctro.2026.101229_bb0065","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00345-024-05205-9","article-title":"Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy","volume":"42","author":"Saripalli","year":"2024","journal-title":"World. J. Urol."},{"key":"10.1016\/j.ctro.2026.101229_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctro.2024.100806","article-title":"Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy \u2013 a systematic review and meta-analysis of recent trials","volume":"48","author":"Schr\u00f6der","year":"2024","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"10.1016\/j.ctro.2026.101229_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102176","article-title":"Outcomes and toxicities of re-irradiation for prostate cancer: a systematic review on behalf of the re-irradiation working Group of the Italian Association of radiotherapy and clinical oncology (AIRO)","volume":"95","author":"Munoz","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctro.2026.101229_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.681448","article-title":"Salvage reirradiation options for locally recurrent prostate Cancer: a systematic review","volume":"11","author":"Zhong","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ctro.2026.101229_bb0085","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate Cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctro.2026.101229_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111087","article-title":"Magnetic resonance guided stereotactic reirradiation for locally recurrent prostate cancers: long-term results from a prospective registry study","volume":"211","author":"Buchalet","year":"2025","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.ctro.2026.101229_bb0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clon.2019.10.008","article-title":"Single-dose focal salvage high dose rate brachytherapy for locally recurrent prostate Cancer","volume":"32","author":"Chitmanee","year":"2020","journal-title":"Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctro.2026.101229_bb0100","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2021.10.138","article-title":"Salvage low-dose-rate prostate brachytherapy: clinical outcomes of a phase 2 trial for local recurrence after external beam radiation therapy (NRG oncology\/RTOG 0526)","volume":"112","author":"Crook","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctro.2026.101229_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858740","article-title":"1.5T MR-guided daily adaptive stereotactic body radiotherapy for prostate re-irradiation: a preliminary report of toxicity and clinical outcomes","volume":"12","author":"Cuccia","year":"2022","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.ctro.2026.101229_bb0110","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.23.01391","article-title":"Salvage reirradiation for locally recurrent prostate Cancer: results from a prospective study with 7.2 years of follow-up","volume":"42","author":"Ekanger","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctro.2026.101229_bb0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijrobp.2019.10.014","article-title":"Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: efficacy and toxicity of HDR-like SBRT","volume":"106","author":"Fuller","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctro.2026.101229_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.984917","article-title":"Health-related quality of life of salvage prostate reirradiation using stereotactic ablative radiotherapy with urethral-sparing","volume":"12","author":"Greco","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101229_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-021-01839-w","article-title":"Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes","volume":"16","author":"Lewin","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.ctro.2026.101229_bb0130","article-title":"MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer","volume":"12","author":"M\u00e9nard","year":"2022","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.ctro.2026.101229_bb0135","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cncr.22934","article-title":"Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer","volume":"110","author":"Nguyen","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctro.2026.101229_bb0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euo.2023.01.009","article-title":"The safety and efficacy of salvage stereotactic radiation therapy in patients with intraprostatic tumor recurrence after previous external radiation therapy: phase 1 results from the GETUG-AFU 31 study","volume":"6","author":"Pasquier","year":"2023","journal-title":"European Urology Oncology"},{"issue":"5","key":"10.1016\/j.ctro.2026.101229_bb0145","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.ijrobp.2024.02.014","article-title":"A phase 1 trial of salvage stereotactic body radiation therapy for Radiorecurrent prostate Cancer after brachytherapy","volume":"119","author":"Patel","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.ctro.2026.101229_bb0150","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.prro.2023.05.012","article-title":"A phase 1 trial of focal salvage stereotactic body radiation therapy for Radiorecurrent prostate Cancer","volume":"13","author":"Patel","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.ctro.2026.101229_bb0155","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.prro.2025.09.002","article-title":"Salvage stereotactic body radiation therapy for locally recurrent prostate cancer: quality-of-life outcomes from a prospective clinical trial","volume":"16","author":"Patel","year":"2025","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.ctro.2026.101229_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111091","article-title":"Updated results of MR-assisted focal salvage HDR prostate brachytherapy: a prospective study","volume":"211","author":"Paulin","year":"2025","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ctro.2026.101229_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109495","article-title":"Recurrence characteristics after focal salvage HDR brachytherapy in prostate cancer","volume":"180","author":"Rasing","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ctro.2026.101229_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.861127","article-title":"A prospective study of high dose-rate brachytherapy or stereotactic body radiotherapy of intra-prostatic recurrence: toxicity and long term clinical outcome","volume":"12","author":"Ryg","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ctro.2026.101229_bb0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brachy.2013.11.005","article-title":"A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy","volume":"13","author":"Yamada","year":"2014","journal-title":"Brachytherapy"},{"issue":"5","key":"10.1016\/j.ctro.2026.101229_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18050848","article-title":"Reirradiation of local recurrences of prostate Cancer: PROSTARE (PROstate Cancer STereotActic REirradiation) early safety analysis of a phase 2 study with a limited cohort","volume":"18","author":"Majewski","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101229_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2026.111446","article-title":"Prospective phase 2 trial: long-term results of a salvage brachytherapy combined with interstitial hyperthermia as re-irradiation for locally recurrent prostate carcinoma","volume":"218","author":"Strnad","year":"2026","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.ctro.2026.101229_bb0190","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2017.12.013","article-title":"American Association of Physicists in Medicine task group 263: standardizing nomenclatures in radiation oncology","volume":"100","author":"Mayo","year":"2018","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"issue":"2","key":"10.1016\/j.ctro.2026.101229_bb0195","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bju.16150","article-title":"F-SHARP: a phase I\/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer","volume":"133","author":"Solanki","year":"2024","journal-title":"BJU Int."},{"issue":"11","key":"10.1016\/j.ctro.2026.101229_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068580","article-title":"Reirradiation options for previously irradiated prostate cancer (RO-PIP): feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)","volume":"12","author":"Zhong","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctro.2026.101229_bb0205","doi-asserted-by":"crossref","first-page":"104085","DOI":"10.1016\/j.clon.2026.104085","article-title":"Reirradiation options for previously irradiated prostate cancer (RO-PIP): is it feasible to randomize between treatment with stereotactic body radiotherapy (SBRT) versus high dose rate brachytherapy (HDR BT)?: RO-PIP","author":"Zhong","year":"2026","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101229_bb0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eururo.2023.09.001","article-title":"The role of multiparametric MRI and MRI-targeted biopsy in the diagnosis of Radiorecurrent prostate Cancer: an analysis from the FORECAST trial","volume":"85","author":"Light","year":"2024","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101229_bb0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2009.03.013","article-title":"Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer","volume":"92","author":"Fonteyne","year":"2009","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.ctro.2026.101229_bb0220","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2019.07.012","article-title":"Salvage stereotactic body radiation therapy for local prostate Cancer recurrence after radiation therapy: a retrospective Multicenter study of the GETUG","volume":"105","author":"Pasquier","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.ctro.2026.101229_bb0225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother. Oncol."},{"issue":"7","key":"10.1016\/j.ctro.2026.101229_bb0230","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate Cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctro.2026.101229_bb0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"15","key":"10.1016\/j.ctro.2026.101229_bb0240","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"As","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctro.2026.101229_bb0245","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19&#xa0;Gy or two fractions of 13.5&#xa0;Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ctro.2026.101229_bb0250","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.ctro.2026.101229_bb0255","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.adro.2019.05.007","article-title":"The special medical physics consult process for reirradiation patients","volume":"4","author":"Paradis","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101229_bb0260","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S1470-2045(25)00562-5","article-title":"Reirradiation Collaborative group (ReCOG) consensus on standards for dose evaluation and reporting in patients with multiple courses of radiation therapy: an AAPM\/ACRO\/ASTRO\/CARO\/COMP\/CADRA\/CPQR\/ESTRO\/NRG-endorsed consensus statement","volume":"27","author":"Paradis","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctro.2026.101229_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110587","article-title":"<strong>Consistency in reirradiation scenarios: terminology, tissue recovery in calculations, units and reporting<\/strong>","volume":"202","author":"West","year":"2025","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101229_bb0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2025.07.007","article-title":"Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE-B study","volume":"89","author":"Ratnakumaran","year":"2026","journal-title":"Eur. Urol."}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:23:18Z","timestamp":1787257398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"alternative-id":["S2405630826001242"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101229","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG)","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101229"}}